Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024 - 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian...

Distinguished Life Sciences Leaders to be Honored at CLSA's 2015 Pantheon DiNA Awards Ceremony SOUTH SAN FRANCISCO, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- California Life Sciences Association (CLSA), the leading voice to drive innovation for California's life sciences sector, today announced...